Nuclear oncology 1984.
New developments in nuclear oncology, based on monoclonal antibodies and position emission tomography measurement of glucose metabolism promise to broaden the range of applications of nuclear medicine methods in the clinical management of patients with tumor. Perhaps of greatest importance, is the prospect of both diagnosing and treating common solid tumors, with the same radiolabeled (monoclonal antibody) pharmaceutical preparation.
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D001761:Bleomycin / Q000031:analogs & derivatives; D001932:Brain Neoplasms / Q000000981:diagnostic imaging; D003847:Deoxyglucose / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D005710:Gallium Radioisotopes; D005910:Glioma / Q000000981:diagnostic imaging; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000276:immunology / Q000556:secondary; D058950:Melanoma-Specific Antigens; D008875:Middle Aged; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D005710:Gallium Radioisotopes; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; C030187:cobalt bleomycin; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D003847:Deoxyglucose